Abstract
Alpha-particle therapy has received increased attention during the last few years because of the development of new targeting constructs and new labeling techniques and the availability of suitable α-particle – emitting radionuclides. This work provides an overview of methods that have been used in clinical trials in estimating the absorbed dose to tumors and healthy tissue in patients following such α-particle therapy. Similarities and differences compared to conventional therapies using β¯-particle emitters are presented. The specific challenges of establishing accurate dosimetry for α- particles in the individual patient are also discussed, as is the effect that improved patient-specific dosimetry might have on the overall efficacy of this type of therapy.
Keywords: Alpha-particles, clinical trials, dosimetry, radionuclide therapy, regulators, (MTA, PATIENT PHARMACOKINETICS, PATIENT DOSIMETRY, Gamma Counters and Probes, Quantitative Imaging
Current Radiopharmaceuticals
Title: Patient-Specific Alpha-Particle Dosimetry
Volume: 4 Issue: 4
Author(s): Stig Palm, Jorgen Elgqvist and Lars Jacobsson
Affiliation:
Keywords: Alpha-particles, clinical trials, dosimetry, radionuclide therapy, regulators, (MTA, PATIENT PHARMACOKINETICS, PATIENT DOSIMETRY, Gamma Counters and Probes, Quantitative Imaging
Abstract: Alpha-particle therapy has received increased attention during the last few years because of the development of new targeting constructs and new labeling techniques and the availability of suitable α-particle – emitting radionuclides. This work provides an overview of methods that have been used in clinical trials in estimating the absorbed dose to tumors and healthy tissue in patients following such α-particle therapy. Similarities and differences compared to conventional therapies using β¯-particle emitters are presented. The specific challenges of establishing accurate dosimetry for α- particles in the individual patient are also discussed, as is the effect that improved patient-specific dosimetry might have on the overall efficacy of this type of therapy.
Export Options
About this article
Cite this article as:
Palm Stig, Elgqvist Jorgen and Jacobsson Lars, Patient-Specific Alpha-Particle Dosimetry, Current Radiopharmaceuticals 2011; 4 (4) . https://dx.doi.org/10.2174/1874471011104040329
DOI https://dx.doi.org/10.2174/1874471011104040329 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Targeting Ion Channels in Cancer: A Novel Frontier in Antineoplastic Therapy
Current Medicinal Chemistry Oncogenic MicroRNAs in the Genesis of Leukemia and Lymphoma
Current Pharmaceutical Design Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy Aneurysm of the Communicating Vein Between the Left Renal Vein and Left Ascending Lumbar Vein Mimicking Retroperitoneal Lymphadenopathy: A Case Report
Current Medical Imaging Cancer Neovascularization and Proinflammatory Microenvironments
Current Cancer Drug Targets Curcumin Sensitizes Cancers Towards TRAIL-induced Apoptosis via Extrinsic and Intrinsic Apoptotic Pathways
Current Drug Targets 4-Aminocyclopentane-1,3-diols as Platforms for Diversity: Synthesis of Anandamide Analogs
Medicinal Chemistry Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges
Current Cancer Drug Targets Smac-Derived Aza-Peptide As an Aminopeptidase-Resistant XIAP BIR3 Antagonist
Protein & Peptide Letters Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells
Current Medicinal Chemistry Molecular Biology, Pharmacology and Functional Role of the Plasma Membrane Dopamine Transporter
CNS & Neurological Disorders - Drug Targets Development of Therapeutics for High Grade Gliomas Using Orthotopic Rodent Models
Current Medicinal Chemistry Reduction of Oxidative/Nitrosative Stress in Brain and its Involvement in the Neuroprotective Effect of n-3 PUFA in Alzheimer’s Disease
Current Alzheimer Research Biological and Pharmacological Activities of Iridoids: Recent Developments
Mini-Reviews in Medicinal Chemistry A Connecting Switch Among Aging, Diabetes and Tumor: Avenue Leading to Cancer Therapeutics
Current Cancer Therapy Reviews It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
Current Topics in Medicinal Chemistry Recent Development of Peptide Drugs and Advance on Theory and Methodology of Peptide Inhibitor Design
Medicinal Chemistry